{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013088","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.652612+00:00","generated_at":"2026-05-15T08:42:01.775582+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MAIA presents THIO-101 data at ELCC showing sustained response in relapsed NSCLC","bullets":["Poster presented at European Lung Cancer Congress 2026 in Copenhagen on March 27, 2026.","Data from THIO-101 trial: Ateganosine + ICI in relapsed NSCLC patients.","Poster title indicates sustained response and long-term therapeutic benefits after treatment cessation.","No financial or numerical efficacy data disclosed in the 8-K; poster available on company website."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013088","json":"https://secwatch.observer/filing/0001493152-26-013088.json","markdown":"https://secwatch.observer/filing/0001493152-26-013088.md","text":"https://secwatch.observer/filing/0001493152-26-013088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000149315226013088/0001493152-26-013088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000149315226013088/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:42:01.775582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}